Table 1.
Descriptive statistics of clinic-pathological variables of study population.
| Overall (N = 88) | |
|---|---|
| Sex | |
| Female | 27 (30.7%) |
| Male | 61 (69.3%) |
| Age | |
| ≥70 | 42 (47.7%) |
| <70 | 46 (52.3%) |
| Never Smokers | |
| yes | 6 (6.8%) |
| no | 82 (93.2% |
| ECOG | |
| 0 | 40 (45.5%) |
| 1 | 48 (54.5%) |
| Treatment | |
| Nivolumab | 35 (39.8%) |
| Pembrolizumab | 53 (60.2%) |
| Setting | |
| Second or Third Line | 51 (58.0%) |
| First Line | |
| Histology | |
| Adenocarcinoma | 63 (71.6%) |
| Squamous Cell Carcinoma | 25 (28.4%) |
| EGFR | |
| Mutated | 4 (4.5%) |
| Wild Type | 84 (95.5%) |
| PDL1 Staining | |
| <50% | 44 (50.0%) |
| ≥50% | 44 (50.0%) |
| Primary Tumor | |
| Not Resected | 63 (71.6%) |
| Resected | 25 (28.4%) |
| Tumor Burden | |
| ≥115 mm | 45 (51.1%) |
| <115 mm | 43 (48.9%) |
| Brain Metastasis | |
| Yes | 19 (21.6%) |
| No | 69 (78.4%) |
| Liver Metastasis | |
| Yes | 17 (19.3%) |
| No | 71 (80.7%) |
| Lung Metastasis | |
| Yes | 54 (61.4%) |
| No | 34 (38.6%) |
| Bone Metastasis | |
| Yes | 52 (59.1%) |
| No | 36 (40.9%) |
| Pleural Effusion | |
| Yes | 17 (19.3%) |
| No | 71 (80.7%) |
| Adrenal Metastasis | |
| Yes | 72 (81.8%) |
| No | 16 (18.2%) |
| Soft Tissue Metastasis | |
| Yes | 6 (6.8%) |
| No | 82 (93.2%) |
| Nodel Metastasis | |
| Yes | 69 (78.4%) |
| No | 19 (21.6%) |
| Other Site Metastasis | |
| Yes | 11 (12.5%) |
| No | 77 (87.5%) |